- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01494766
Efficacy of Tyrosine in Restless Legs Syndrome
April 25, 2017 updated by: Seton Healthcare Family
Pilot Study of the Efficacy of Tyrosine in Restless Legs Syndrome
Tyrosine is a non essential amino acid that is the precursor of the neurotransmitter, dopamine.
Tyrosine is converted into Levodihydrophenylalanine (L-Dopa) and L-Dopa is subsequently and avidly converted into dopamine.
It is well known that dopamine deficiency leads to the manifestations of restless legs syndrome (RLS).
Studies have shown dopamine agonists and L-dopa to be effective in controlling symptoms.
No studies to date have been done to determine the role of tyrosine in RLS.
This open-label pilot study aims to determine the efficacy and tolerability of tyrosine in RLS, as current agents have limitations in treating RLS in addition to adding another possible agent to the investigators arsenal of treating RLS that maybe more cost efficient.
In this pilot study, the dose of tyrosine will be escalated from 750 mg once daily by mouth (PO) up to 3000 mg once daily PO, as tolerated, in increments of 750 mg every week in patients who meet the inclusion criteria for RLS.
Patients' symptoms will be monitored on a weekly basis for six weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78701
- Seton Family of Hospitals
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women aged 18 to 80 years and
- Newly diagnosed (medication-naïve) as having restless legs syndrome (using the International Restless Legs Syndrome Study Group (IRLSSG20) diagnostic criteria with a score of greater than or equal to 15, see Appendix A) and
- That interfered with sleep onset and/or maintenance for greater than four nights/week for a minimum of six months
- Currently not receiving treatment for RLS
Exclusion Criteria:
- Patients suffering from secondary RLS (other movement and/or primary sleep disorders, chronic renal insufficiency - calculated from the creatinine clearance, and/or iron deficiency - baseline serum ferritin level less than 10 ng/ml)
- Patients currently on pharmacotherapy for RLS (not medication-naïve) or previous use of pharmacotherapy for RLS in the past
- Patients that are pregnant and/or breastfeeding
- Patients that are on levothyroxine or monoamine oxidase inhibitors
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Tyrosine
Dietary Supplement: L-Tyrosine Other Names: NOW Brand L-Tyrosine 750 mg Tablets -Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study. |
L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
International RLS Survey Group (IRLSSG20) Score
Time Frame: 6 weeks
|
Use of this survey to be used as a marker for severity of RLS symptoms and therefore efficacy of this medication.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical global impression-global improvement (CGI-I) scale
Time Frame: 6 weeks
|
Use of the CGI-I scale as a secondary outcome measure to determine severity of RLS symptoms and efficacy of medication.
|
6 weeks
|
Medical Outcomes Study - Sleep Scale (MOS-SS)
Time Frame: 6 weeks
|
Use of the MOS-SS to determine severity of RLS symptoms and efficacy of medication.
|
6 weeks
|
Case Report Form
Time Frame: 6 weeks
|
Use of a history and physical examination (limited neurological exam) to be used as a secondary assessment measure of RLS symptom severity and medication efficacy.
They will be charted in case report format.
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Actual)
May 1, 2012
Study Completion (Actual)
November 1, 2012
Study Registration Dates
First Submitted
December 15, 2011
First Submitted That Met QC Criteria
December 16, 2011
First Posted (Estimate)
December 19, 2011
Study Record Updates
Last Update Posted (Actual)
April 27, 2017
Last Update Submitted That Met QC Criteria
April 25, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR-11-146
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Restless Legs Syndrome (RLS)
-
XenoPort, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
Astellas Pharma IncCompletedRestless Legs Syndrome (RLS)Japan
-
XenoPort, Inc.CompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)
-
GlaxoSmithKlineCompleted12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome ((CR-RLS))Restless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)Spain, United States, Belgium, Sweden, Australia, Netherlands, United Kingdom, Italy, Austria, Germany, Denmark, France, Norway
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
University Hospital, MontpellierCompletedRestless Legs Syndrome (RLS)France
Clinical Trials on L-Tyrosine
-
Thomas HopeActive, not recruitingRecurrent Glioblastoma | Recurrent WHO Grade III Glioma | Low Grade Glioma | Intracranial Neoplasm | Recurrent World Health Organization (WHO) Grade II GliomaUnited States
-
New York Institute of TechnologyCompletedBlood PressureUnited States
-
Hadassah Medical OrganizationUnknown
-
Asan Medical CenterRecruitingPatients With Suspected or Diagnosed Central Nervous System LymphomaKorea, Republic of
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
IntraBio IncCompletedNiemann-Pick Disease, Type CUnited States, United Kingdom, Germany, Slovakia, Spain
-
John D. Dingell VA Medical CenterWithdrawnDepressionUnited States
-
Charite University, Berlin, GermanyUnknown
-
Centre Hospitalier Universitaire de NiceNot yet recruiting
-
University Hospital, ToulouseCompleted